Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured i...

FDA Drug Recall #D-1204-2018 — Class II — September 11, 2018

Recall Summary

Recall Number D-1204-2018
Classification Class II — Moderate risk
Date Initiated September 11, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Torrent Pharma Inc.
Location Kalamazoo, MI
Product Type Drugs
Quantity 15,384 30-count bottles

Product Description

Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured in INDIA, For: TORRENT PHARMA INC., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920. NDC: 13668-342-30

Reason for Recall

Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.

Distribution Pattern

Nationwide USA

Lot / Code Information

Lot: BFR5D002 EXP 11-2019

Other Recalls from Torrent Pharma Inc.

Recall # Classification Product Date
D-0455-2025 Class II Fluoxetine Tablets, USP, 20 mg, 30-count bottl... May 27, 2025
D-0456-2025 Class II Fluoxetine Tablets, USP, 20 mg, 28-count Carton... May 27, 2025
D-0365-2022 Class II Carbamazepine Tablets, USP 200 mg 100 Tablets R... Dec 2, 2021
D-0285-2022 Class III Telmisartan and Hydrochlorothiazide Tablets, US... Dec 1, 2021
D-1317-2020 Class II Carbamazepine Tablets, USP 200 mg, packaged in ... May 11, 2020

Frequently Asked Questions

Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.